*Tarceva is a targeted cancer treatment. Tarceva is designed to block cell tumor cell growth by targeting the protein in your body called the Human Epidermal Growth Factor Receptor 1 (HER1/ EGFR).
Indication and Usage for Lung Cancer Patients
TARCEVA monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Results from two, multicenter, placebo-controlled, randomized, Phase 3 trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of TARCEVA with platinum-based chemotherapy [carboplatin and paclitaxel or gemcitabine and cisplatin] and its use is not recommended in that setting.
Indication and Usage for Pancreatic Cancer Patients
TARCEVA in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Important Information to Know
In clinical studies, there were infrequent reports of serious lung injuries similar to Interstitial Lung Disease (ILD)-like events. Reports of ILD-like events have been serious and have included deaths in patients receiving Tarceva.
Patients receiving Tarceva plus gemcitabine were more likely to experience bleeding and clotting problems such as heart attack or stroke.
Tarceva may cause harm to an unborn baby or may cause possible risk or pregnancy loss. Women should avoid becoming pregnant and avoid breast feeding while taking Tarceva.
You should call your doctor right away if you have these signs or symptoms: new or worsening shortness of breath and cough; serious or ongoing diarrhea, nausea, loss of appetite or vomiting; eye irritation.
Rash and diarrhea were the most common side effects associated with the use of Tarceva in non-small cell lung cancer (NSCLC) clinical studies.
Fatigue, rash, nausea, loss of appetite and diarrhea were the most common side effects associated with the use of Tarceva plus gemcitabine in pancreatic clinical studies.
Tarceva is not right for everyone. Ask your doctor if once daily Tarceva is right for you.
are trademarks of OSI Pharmaceuticals, Inc.